Addressing small sample size bias in multiple‐biomarker trials: Inclusion of biomarker‐negative patients and Firth correction

Habermehl Christina; Benner Axel; Kopp‐Schneider Annette

首页> 外文期刊>Biometrical Journal >Addressing small sample size bias in multiple‐biomarker trials: Inclusion of biomarker‐negative patients and Firth correction

【24h】

Addressing small sample size bias in multiple‐biomarker trials: Inclusion of biomarker‐negative patients and Firth correction

机译：解决多生物标志物试验中的小样本大小偏差：将生物标志物 - 负患者含有和磁阵校正

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biometrical Journal》 |2018年第2期|共13页
作者
Habermehl Christina; Benner Axel; Kopp‐Schneider Annette;
展开▼
作者单位

Department of BiostatisticsGerman Cancer Research Center (DKFZ)Heidelberg Germany;

Department of BiostatisticsGerman Cancer Research Center (DKFZ)Heidelberg Germany;

Department of BiostatisticsGerman Cancer Research Center (DKFZ)Heidelberg Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类生物学实验与观测;
关键词
biomarkers; biomarker‐negative patients; Cox proportional hazards model; Firth correction; small sample size bias; Survival; Umbrella trials;

机译：生物标志物;生物标志物 - 阴性患者;Cox比例危险模型;圆形校正;小样本大小偏见;存活;伞试验;

相似文献

外文文献
中文文献
专利

1. Addressing small sample size bias in multiple‐biomarker trials: Inclusion of biomarker‐negative patients and Firth correction [J] . Habermehl Christina, Benner Axel, Kopp‐Schneider Annette Biometrical Journal . 2018,第2期

机译：解决多生物标志物试验中的小样本大小偏差：将生物标志物 - 负患者含有和磁阵校正
2. The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients [J] . Jens-Ulrik Jensen, Bettina Lundgren, Lars Hein, BMC Infectious Diseases . 2008,第1期

机译：降钙素原和生存研究（PASS）–一项由多中心研究人员发起的随机试验，旨在研究每日测量的生物标志物降钙素原和对降钙素原水平异常的主动诊断和治疗反应是否可以改善重症监护病房患者的生存率。计算的样本量（目标人群）：1000位患者
3. Sample size and threshold estimation for clinical trials with predictive biomarkers [J] . MackeyH.M., BengtssonT. Contemporary clinical trials . 2013,第2期

机译：具有预测性生物标志物的临床试验的样本量和阈值估计
4. New approaches to the detection of cancer biomarkers fromsmall sample sizes using laser capture microdissection with mass spectrometry [C] . International Beijing conference and exhibition on instrumental analysis;BCEIA 2003 . 2003

机译：激光捕获显微切割结合质谱从小样本中检测癌症生物标志物的新方法
5. Prognostic biomarker detection, machine learning bias correction, and differential coexpression module detection. [D] . Ding, Ying. 2014

机译：预后生物标志物检测，机器学习偏倚校正和差异共表达模块检测。
6. The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients [O] . Jens-Ulrik Jensen, Bettina Lundgren, Lars Hein, 2008

机译：降钙素原和生存研究（PASS）–一项由多中心研究人员发起的随机试验旨在调查每日测量的生物标志物降钙素原和对降钙素原水平异常的主动诊断和治疗反应是否可以改善重症监护病房患者的生存率。计算的样本量（目标人群）：1000位患者
7. Correction to: Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker‑Driven Phase III Trial [O] . Akira Takazawa, Satoshi Morita 2020

机译：纠正：生物标志物驱动阶段试验的研究设计和样本量的最佳决策标准

Addressing small sample size bias in multiple‐biomarker trials: Inclusion of biomarker‐negative patients and Firth correction

著录项

相似文献

相关主题

期刊订阅